Clinical trials
PSMA clinical trials
Below are recruiting psma clinical trials, each written for real people, not researchers. We’re tracking 197 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06320223Recruiting
PSMA PET scan registry for prostate cancer outcomes
This registry collects information from people with prostate cancer who have had a PSMA PET scan. Researchers want to learn how well this scan predicts outcomes over at least 3 years, which may help improve future care.
EssenAges 18 years+ - NCT06363435Recruiting
AI study of tumor burden on PSMA PET-CT scans
This trial tests an AI tool that measures tumor burden on PSMA PET-CT scans. If you are having this scan for prostate cancer, it could help doctors get more detailed information from your images.
LundAges 20–120 - NCT06450548Recruiting
PSMA and FDG PET scans before 177Lu-PSMA therapy
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
RouenAges 18 years+ - NCT06494696Recruiting
PSMA PET/MRI with MRI for prostate cancer risk
This study tests whether a special scan (PSMA PET/MRI) combined with a standard MRI can better detect prostate cancer. It is for men who have not had a biopsy yet and are suspected of having prostate cancer.
Taoyuan CityAges 40–85 - NCT06560905RecruitingPhase 2
PSMA-PET scan before melanoma surgery
This trial tests if a special scan (PSMA-PET) can help plan surgery for melanoma that has spread to lymph nodes. It may help doctors remove all cancer more accurately.
LondonAges 18 years+ - NCT06565247RecruitingPhase 3
Comparing PET and MRI scans before prostate cancer surgery
This trial tests if a special PET scan (PSMA-PET) plus MRI is better than MRI alone at finding the full extent of high-risk prostate cancer before surgery. It aims to improve surgical planning by checking scan results against the removed prostate tissue.
MalmöAges 18 years+ - NCT06574880RecruitingPhase 1/Phase 2
Radiation and Lutetium PSMA for locally advanced prostate cancer
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
Cleveland, OhioAges 18 years+ - NCT06690970Recruiting
PSMA PET/CT scan for people with or suspected to have cancer
This study is looking at how well a special type of PET/CT scan (called PSMA PET/CT) can see cancer in people who have or may have certain tumors. It may help doctors better understand and track the disease.
Hefei, AnhuiAges 18–80 - NCT06756334RecruitingEarly Phase 1
Comparing Two PET/CT Scans for Prostate Cancer
This study compares two types of PET/CT scans (using different radioactive tracers) to see which one is better at finding prostate cancer, detecting if it has come back, or spotting spread to other parts of the body. You will get both scans so doctors can compare them directly.
Hefei, AnhuiAges 18–90 - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Los Angeles, CaliforniaAges 18–100 - NCT06852820RecruitingPhase 2
PSMA-targeted radioactive therapy for advanced liver cancer
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
Cleveland, OhioAges 18 years+ - NCT06972628RecruitingPhase 2
177Lu-PSMA-617 for advanced prostate cancer with bone spread
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Houston, TexasAges 18 years+ - NCT06999837Recruiting
PSMA PET/CT scan for liver cancer (HCC)
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
ClichyAges 18 years+ - NCT07054346RecruitingPhase 1
Comparing two radiation drugs for high-risk prostate cancer before surgery
This trial tests two radioactive drugs (Lu-177 and Ac-225 PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that hasn't spread far. The goal is to see which drug works better at targeting cancer cells.
San Francisco, CaliforniaAges 18 years+ - NCT07056790RecruitingPhase 1/Phase 2
PET scan using 68Ga-PSMA-CYC for prostate cancer
This trial is testing a new type of PET scan that uses a special tracer called 68Ga-PSMA-CYC to take detailed pictures of prostate cancer. It may help doctors better see where the cancer is and how far it has spread.
Fuzhou, FujianAges 18–80 - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07209878RecruitingPhase 2/Phase 3
PET scan vs. MRI for prostate cancer diagnosis
This trial compares two types of imaging scans (a PSMA PET scan and an MRI) to see which is better at finding prostate cancer. You may be able to join if you are scheduled for prostate removal surgery and haven't started cancer treatment yet.
Fuzhou, FujianAges 18–80 - NCT07219147RecruitingPhase 1
Combination treatment for advanced prostate cancer
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07234981RecruitingPhase 2
Using PSMA-PET to guide less intense radiation for returning prostate cancer
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
Omaha, NebraskaAges 30 years+ - NCT07258056Recruiting
Using PET/MRI to find prostate cancer after a normal MRI
This study uses a special type of PET/MRI scan and targeted biopsies to find prostate cancer in men who have a high PSA density but a normal MRI or negative biopsy. It aims to better detect cancer that may be missed by standard tests.
Aarhus N, AarhusAges 18 years+ - NCT07511933Recruiting
New PET scan to detect tumor regrowth vs. scar tissue in brain
This study tests a new type of PET scan (a special imaging test) that uses a radioactive tracer to help doctors tell the difference between scar tissue from past radiation and cancer that has come back in the brain. This could help avoid unnecessary surgery or additional treatment.
AmsterdamAges Any age - NCT07531329Recruiting
Delayed PSMA imaging to detect aggressive prostate cancer
This study tests whether a special type of imaging scan (PSMA PET/CT with delayed imaging) can better identify aggressive prostate cancer in men who haven't had a biopsy yet. The goal is to help doctors decide who really needs a biopsy and avoid unnecessary procedures.
Lanzhou, GansuAges 18 years+ - NCT07553780Recruiting
Tracking Prostate Cancer Response Using PSMA Imaging Scans
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
Lanzhou, GansuAges 18 years+
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma?
- Yes. Clin2 currently lists 197 recruiting psma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.